Guidance
Changes after publication
October 2018: The recommendations and section 2 were updated because the marketing authorisation for romiplostim now includes people who have not had a splenectomy.
May 2014: The recommendation wording has been updated in line with NICE's existing wording conventions and the wording used in NICE technology appraisal guidance 293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205).
February 2014: minor maintenance
March 2012: minor maintenance